ReviewEndocrinology and metabolism (Seoul, Korea)2016
Recent Updates on the Management of Medullary Thyroid Carcinoma.
Review in Endocrinology and metabolism (Seoul, Korea), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Clinicopathological Significance and Prognosis of Medullary Thyroid Microcarcinoma: A Meta-analysis.World journal of surgery · 2017Pooled it
- Epigenetic Modifications as Novel Biomarkers for Diagnosis, Prognosis, and Therapeutic Targeting in Thyroid, Pancreas, and Lung Neuroendocrine Tumors.Journal of clinical medicine · 2025Review
- Medullary Thyroid Carcinoma in Patients with Graves' Disease-A Case Series and Literature Review.Journal of clinical medicine · 2024Article
- Article
- [European journal of nuclear medicine and molecular imaging · 2023Article
- Evaluation of PD-L1 antigen expression using immunohistochemistry technique in medullary thyroid carcinoma samples.International journal of physiology, pathophysiology and pharmacology · 2023Article
- Metformin Decreases Serum Thyroglobulin Concentration in Nonmedullary Thyroid Carcinoma.Journal of the Endocrine Society · 2022Article
- Multiple endocrine neoplasia 2: an overview.Therapeutic advances in chronic disease · 2022Review
- Effects of marital status on survival of medullary thyroid cancer stratified by age.Cancer medicine · 2021Article
- Decision Making When Cancer Becomes Chronic: Needs Assessment for a Web-Based Medullary Thyroid Carcinoma Patient Decision Aid.JMIR formative research · 2021Article
- Long non-coding RNA LINC00488 facilitates thyroid cancer cell progression through miR-376a-3p/PON2.Bioscience reports · 2021Article
- Long Non-coding RNA RUNDC3A-AS1 Promotes Lung Metastasis of Thyroid Cancer via Targeting the miR-182-5p/ADAM9.Frontiers in cell and developmental biology · 2021Article
- Medullary thyroid cancer: epidemiological pattern and factors contributing to recurrence and metastasis.Annals of the Royal College of Surgeons of England · 2020Article
- Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Article
- Kinase Inhibitors in the Treatment of Thyroid Cancer: Institutional Experience.Acta clinica Croatica · 2020Review
- Multiple Auer Rods in Fine-Needle Aspiration Smears of Medullary Thyroid Carcinoma: An Unusual Finding.International medical case reports journal · 2020Article
- Lymph Node Metastases of Medullary Thyroid Cancer: Role of Calcitonin in the Washout Fluid of Fine-Needle Aspiration.International journal of endocrinology · 2020Article
- [Imaging of medullary thyroid carcinoma].Der Radiologe · 2019Review
- Shikonin Inhibites Migration and Invasion of Thyroid Cancer Cells by Downregulating DNMT1.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Recent Development of Nuclear Molecular Imaging in Thyroid Cancer.BioMed research international · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor derived from the thyroid C cells producing calcitonin. MTC accounts for 0.6% of all thyroid cancers and incidence of MTC increased steadily between 1997 and 2011 in Korea. It occurs either sporadically or in a hereditary form based on germline rearranged during transfection (RET) mutations. MTC can be cured only by complete resection of the thyroid tumor and any loco-regional metastases. The most appropriate treatment is still less clear in patients with residual or recurrent disease after initial surgery or those with distant metastases because most patients even with metastatic disease have indolent courses with slow progression for several years and MTC is not responsive to either radioactive iodine therapy or thyroid-stimulating hormone suppression. Recently, two tyrosine kinase inhibitors (TKIs), vandetanib and cabozantinib, are approved for use in patients with advanced, metastatic or progressive MTC. In this review, we summarize the current approach according to revised American Thyroid Association guidelines and recent advances in systemic treatment such as TKIs for patients with persistent or recurrent MTC after surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.